Audentes (BOLD) Reports Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With XLMTM
January 4, 2018 7:06 AM
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
